Relay Therapeutics to Join Notable Investor Conferences in September
Relay Therapeutics Announces Participation in Upcoming Investor Conferences
Relay Therapeutics, Inc. (Nasdaq: RLAY), based in Cambridge, Massachusetts, is making significant strides in the development of cutting-edge therapies aimed at transforming the lives of individuals battling cancer and genetic diseases. The company recently shared that its management team will engage in two prominent fireside chats scheduled for September.
Details on Conferences
The first event is the 2025 Wells Fargo Healthcare Conference, set for September 4, 2025, at 2:15 PM ET. Following shortly after, Relay Therapeutics will also be part of the Morgan Stanley 23rd Annual Global Conference, occurring on September 10, 2025, at 11:30 AM ET. These fireside chats are poised to be informative moments where management will discuss the company’s intricate initiatives and breakthroughs in precision medicine.
Accessing the Webcasts
Both discussions will be available for live streaming on Relay Therapeutics’ official website, particularly in the News & Events section. For those unable to attend the live sessions, archived replays will be accessible for up to 30 days post-event, ensuring that interested parties remain informed about the latest developments.
About Relay Therapeutics
Relay Therapeutics is recognized for its pioneering work in small molecule precision medicine. The firm is committed to advancing potentially transformative therapies for patients grappling with cancer and genetic disorders. Central to Relay's research is the innovative Dynamo platform, which combines state-of-the-art computational and experimental methodologies to target previously unapproachable protein targets. This platform positions Relay strongly at the forefront of medical innovation.
Clinical Advancement of RLY-2608
Relay's flagship clinical asset, RLY-2608, stands out as the first pan-mutant selective PI3K? inhibitor currently in clinical development. This innovative treatment is presently undergoing a Phase 3 trial, known as ReDiscover-2, focusing on HR+/HER2- metastatic breast cancer. In addition to this, RLY-2608 is also being evaluated for a set of genetic disease conditions characterized by PI3K?-driven vascular malformations.
Research Pipeline and Future Prospects
Looking ahead, Relay Therapeutics is nurturing a robust pipeline that includes several late-stage research initiatives targeting NRAS-driven solid tumors and the rare Fabry disease. The company remains committed to pushing the boundaries of what's possible in precision medicine, making significant impacts on patient care and treatment outcomes.
Stay Updated with Relay Therapeutics
More detailed information about Relay Therapeutics and its innovative approaches to therapy can be found on the company’s official website. They also invite individuals to connect and follow their latest updates on LinkedIn, ensuring that community members stay informed about their ongoing research and developments.
Contact Information
For inquiries regarding corporate affairs or media relations, interested parties can reach out to Pete Rahmer at prahmer@relaytx.com, or for media-related concerns, connect with Dan Budwick at 1AB by calling 973-271-6085 or emailing dan@1abmedia.com.
Frequently Asked Questions
What is Relay Therapeutics known for?
Relay Therapeutics is known for its work in developing precision medicines, specifically targeting cancer and genetic diseases through innovative therapies.
When are the upcoming investor conferences?
The conferences are the Wells Fargo Healthcare Conference on September 4, 2025, and the Morgan Stanley Global Conference on September 10, 2025.
How can I access the conference webcasts?
The live webcasts can be accessed through Relay Therapeutics’ website, specifically in the News & Events section.
What is RLY-2608?
RLY-2608 is Relay's lead clinical asset, a selective PI3K? inhibitor currently being tested in trials for metastatic breast cancer.
How can I stay updated with Relay Therapeutics?
You can visit Relay’s official website and follow their LinkedIn page for the latest updates on their research and developments.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.